Peptide-drug conjugates (PDCs) are the peptide analog of antibody-drug conjugates — a tumor-targeting peptide linked to a cytotoxic payload. The platform sits at the intersection of medicinal chemistry, peptide stability work, and ADC-style delivery.
Lead programs covered on this site: Bicycle Therapeutics' bicyclic peptide-toxin conjugates (BT5528 against EphA2, BT8009 against Nectin-4), Avacta's pre|CISION platform (AVA6103 with exatecan), Lirum's LX-101 against IGF-1R for Ewing sarcoma, and the broader academic peptide-payload work covered at AACR and ASCO. Several have followed ADC-style linker chemistry while keeping the peptide targeting moiety.
Stories here cover trial readouts, partnership deals, and the chemistry papers behind the platform. See #peptide-drug-conjugates for the alternate tag and #bicycle-therapeutics for the leading company.
Researchers at Fudan University reported in ACS Nano on October 13, 2026 a peptide-drug conjugate that links a two-part targeting peptide to luteolin, a plant compound, packaged in nanoparticles that release it in response to oxidative stress. Aimed at pericytes, the cells that support blood-brain barrier vessels, it reduced barrier leakage and immune-cell infiltration and promoted myelin repair in two mouse models of multiple sclerosis, and injection under the skin every other day raised brain exposure 2.65-fold and beat daily intravenous dosing. The results are from mice.
Oncopeptides reported on October 9, 2026 that in the open-label INSULA window-of-opportunity study at Oslo University Hospital, active drug was found in resected tumor tissue from the first three patients with recurrent glioblastoma given melflufen, its EMA-approved peptide-drug conjugate, before surgery, meeting the study's primary goal of showing the drug crosses the blood-brain barrier. The company said tumor drug levels matched what animal studies predicted but gave no numbers, and the study is not designed to show clinical benefit. It plans to enroll about 10 patients and will discuss the data in an investor webcast on October 12.
Oncopeptides announced on Thursday, September 17, 2026 that the European Medicines Agency's CHMP adopted a positive opinion to extend the indication of Pepaxti (melflufen), given with dexamethasone, to adults with multiple myeloma who have had at least two prior lines of therapy and whose disease is refractory to lenalidomide and to the last line of therapy. Pepaxti's current EU label covers fourth-line and later patients whose disease is triple-class refractory, so the change would drop that requirement; the opinion rests on the Phase 3 OCEAN trial, and the European Commission is expected to decide within 30 to 60 days. Oncopeptides CEO Sofia Heigis said the broader label 'effectively doubles' the company's addressable patient population. The FDA withdrew the U.S. approval of the same drug, sold there as Pepaxto, on February 23, 2024, after concluding that the OCEAN confirmatory trial did not confirm its clinical benefit.
Avacta Group announced on Friday, September 25, 2026 that it would present the design of its Phase 1a FOCUS-01 trial and new preclinical data for AVA6103 (FAP-Exd) on September 26 at the AACR Conference on Pancreatic Cancer in San Diego. AVA6103 is a peptide-drug conjugate built on Avacta's pre|CISION platform, which is designed to be cleaved inside the tumor by fibroblast activation protein (FAP) so that the chemotherapy payload exatecan is released there, limiting exposure elsewhere in the body. The company said AVA6103 was well tolerated through the first three dose levels, up to a payload dose about 50% above the maximum tolerated dose of conventional exatecan, and that enrollment continues at dose level 4, including an every-two-weeks arm for pancreatic cancer. In mice implanted with human tumor tissue, Avacta reported durable complete and partial responses lasting weeks after dosing stopped; it released no efficacy data from patients.
ITM Isotope Technologies Munich SE received a Complete Response Letter (CRL) from the US FDA on August 7, 2026, disclosed August 10-11, for 177Lu-edotreotide (ITM-11), a somatostatin analog radioligand peptide therapeutic under investigation for gastroenteropancreatic neuroendocrine tumors (GEP-NETs). The CRL cited chemistry, manufacturing, and controls (CMC) and third-party commercial manufacturing facility items that must be addressed before the application can be approved. Notably, the FDA did not identify any concerns regarding the clinical data package, nonclinical data, or safety profile of ITM-11. The COMPETE trial (NCT03049189) evaluated 177Lu-edotreotide compared to everolimus (an oral mTOR inhibitor targeted molecular therapy) in patients with inoperable, progressive Grade 1 or Grade 2 GEP-NETs. ITM-11 is a peptide radioligand therapy: a somatostatin receptor 2 (SSTR2)-targeting peptide chelated to the beta-emitting radionuclide lutetium-177 to deliver targeted radiation to SSTR2-expressing neuroendocrine tumor cells. The category is anchored commercially by Novartis's Lutathera (177Lu-dotatate) and Pluvicto (177Lu-vipivotide tetraxetan, PSMA-targeting for prostate cancer). ITM intends to resubmit and complete the NDA review process. The manufacturing-focused CRL is a substantially better outcome than a clinical-data CRL: resolution timelines for CMC-only CRLs typically run 4-8 months versus 12+ months for data-driven CRLs, and the fundamental commercial thesis remains intact.
Nature published a landmark anticancer peptide study on aMPC16-CA50, a synthetic acid-responsive membranolytic peptide that induces immunogenic membranolytic cell death (MCD) in tumor cells and substantially potentiates immune checkpoint blockade (anti-PD-1/PD-L1) therapy in preclinical mouse tumor models. The peptide is designed to respond to the acidic microenvironment of tumor tissue: at neutral pH the peptide remains inactive, but at the lower pH characteristic of tumor tissue (pH 6.0-6.5) the peptide undergoes conformational changes that allow it to insert into tumor cell membranes and induce membranolytic damage. The resulting cell death is immunogenic (releases damage-associated molecular patterns that alert the immune system) rather than apoptotic (which is typically immunologically silent), producing a mechanism that synergizes with checkpoint inhibitor therapy. The membranolytic mechanism differentiates aMPC16-CA50 from both traditional chemotherapy (which typically induces apoptosis) and from antibody-drug conjugates and CAR-T cell therapies. The paper extends the anticancer-peptide research trajectory that has moved through preclinical validation into early clinical translation with products including Cybrexa Therapeutics's CBX-12 (26-amino-acid peptide-drug conjugate for platinum-resistant ovarian cancer, Phase 2 ongoing) and Novartis's Pluvicto (lutetium-177 vipivotide tetraxetan, PSMA-targeting radiopeptide approved for metastatic prostate cancer).
Pathos AI announced Wednesday August 5, 2026 a $2.09 billion licensing deal with Jiangsu Alphamab Biopharmaceuticals Co. Ltd. for a TROP2/HER3 bispecific antibody-drug conjugate (ADC). The deal extends the ADC modality deal-making cycle that has produced substantial cross-border capital deployment across 2025-2026, notably including Merck's Chugai ADC franchise deal, AbbVie's 2023 ImmunoGen acquisition, the ongoing Pfizer-Seagen (Seattle Genetics) commercial integration, and the emerging peptide-drug conjugate (PDC) franchise developments. The Pathos AI-Alphamab deal complements the July 6 Novartis-Myricx $1.5 billion peptide-drug-conjugate alliance (upfront + biobucks) covered on the site's July digest. TROP2 (trophoblast cell surface antigen 2) is a well-validated oncology target with existing approved ADCs including AstraZeneca-Daiichi Sankyo's Trodelvy (sacituzumab govitecan) for triple-negative breast cancer; HER3 is a differentiated payload delivery target with limited approved-drug precedent. The bispecific ADC combines the two payload-targeting mechanisms in a single molecule with the goal of expanding tumor-cell-targeting selectivity and reducing off-target toxicity relative to single-target ADCs. Pathos AI is a US oncology-focused biotech backed by AI-driven target identification and drug-discovery platforms.
Indena and Chemi S.p.A. (Italfarmaco Group) announced a strategic partnership in June 2026 combining peptide chemistry and high-potency API (HPAPI) conjugation expertise to position both firms as development and manufacturing partners for biotech and pharmaceutical companies pursuing peptide-drug conjugates (PDCs). Under the agreement, Chemi supplies the peptide carrier molecules and Indena handles the conjugation with highly potent payload molecules. Neither company is developing proprietary PDC drugs; the partnership reflects the broader CDMO consolidation pattern as the PDC modality scales (six PDCs in Phase 3 trials and ~96 in development globally per the April 2026 ResearchAndMarkets report, with Lutathera as the only FDA-approved standalone PDC after Pepaxto's withdrawal and the Pepaxti EMA expansion application pending). The partnership lands alongside CordenPharma's AmbioPharm acquisition and the broader sector reshaping.
MultiValent Biotherapies announced June 16 a first closing of $27.425 million in Series A financing to advance MVB-101, a PSMA × folate-receptor-alpha (FRα) dual-target peptide-drug conjugate licensed from China-based Coherent Biopharma (originally CBP-1018). MVB-101 binds two validated prostate-cancer targets simultaneously; existing PDCs and radioligand therapies (Pluvicto, Lutathera) hit one target each. MultiValent holds exclusive global rights outside greater China. A Phase 1b/2a clinical trial in a subgroup of prostate cancer patients is planned to start in Q3 2026. The launch adds another oncology PDC to a field still dominated by Pluvicto (lutetium-177 PSMA-617), Lutathera, and Pfizer's AVA6000 FAP-Dox.
Cybrexa Therapeutics' CBX-12, a 26-amino-acid pH-targeted peptide-drug conjugate that delivers a topoisomerase-1 inhibitor selectively to the acidic tumor microenvironment, completed Phase 1 in September 2024 and has moved into Phase 2 for platinum-resistant ovarian cancer. The peptide-drug conjugate field continues to broaden beyond the bicyclic-peptide and FAP-activated approaches already covered at ASCO, with smaller direct-acting peptide carriers gaining traction.
The ASCO Annual Meeting closed June 2 after a week that moved peptide and targeted-conjugate oncology from abstract to podium: Bicycle's bicyclic peptide-drug conjugate and Avacta's FAP-activated conjugate in solid tumors, Mayo's folate-receptor and BioVaxys' survivin peptide vaccines, Sapience's C/EBPβ antagonist in glioblastoma, and PSMA and lead-212 radioligands from Telix and Perspective. Attention now shifts to ADA 2026 in New Orleans and the July 23-24 PCAC compounding vote.
On June 1 Avacta reported updated Phase 1a/1b data for faridoxorubicin (AVA6000), a pre|CISION-enabled, FAP-activated doxorubicin peptide-drug conjugate that releases its payload inside the tumor microenvironment. At the recommended expansion dose of 310 mg/m², nearly three times conventional doxorubicin's 75 mg/m² maximum tolerated dose, toxicity stayed below historical doxorubicin rates, and the salivary gland cancer cohort held multiple confirmed responses: four partial and nine minor responses among 38 evaluable patients.
Avacta's AVA6000 — a fibroblast activation protein (FAP)-activated peptide-drug conjugate releasing doxorubicin selectively in the tumor microenvironment — released Phase 1a/1b data at ASCO 2026 in salivary gland cancers. Of 30 patients in the Phase 1b cohort treated at 250 mg/m² and above, two experienced confirmed partial responses (>30% tumor shrinkage) and seven experienced minor responses (10-30% shrinkage). The combined Phase 1a + 1b disease control rate reached 90%. Phase 1a data in 11 patients at the same dose range showed 1 confirmed partial response, 4 minor responses, 1 progression, and 5 stable disease — a 91% disease control rate. The favorable safety profile continued versus conventional doxorubicin, with no severe cardiac toxicity events. The data anchors Avacta's planned Phase 2/3 expansion in adenoid cystic carcinoma — the most common salivary gland cancer subtype, with no FDA-approved systemic therapy.
Avacta Therapeutics reported unaudited preliminary results for the 12 months ended December 31, 2025 on Tuesday May 19, 2026, and disclosed that the first patient received treatment in FOCUS-01 — the Phase 1 clinical trial of AVA6103, a FAP-activated exatecan peptide-drug conjugate — in March 2026. AVA6103 is the second pre|CISION-enabled candidate in the Avacta clinical pipeline, after AVA6000 (FAP-Dox, which has Phase Ia/Ib data scheduled at ASCO 2026 in salivary gland cancers). The pre|CISION platform attaches a peptide tetrazolyl moiety cleaved by FAP (fibroblast activation protein) overexpressed in cancer-associated fibroblasts, allowing systemic administration of cytotoxic payloads without the dose-limiting toxicity that constrains free exatecan. FOCUS-01 is enrolling adults with advanced solid tumors. AVA6103 expands the platform from doxorubicin (in AVA6000) to exatecan — a topoisomerase I inhibitor with potency advantages in HER2-low and triple-negative breast cancer.
A Nature Communications paper published May 13, 2026 reported that chiral engineering of tripeptide-drug conjugates (PDCs) — systematically varying the L/D amino-acid configuration in the peptide moiety — controls phase behavior between liquid-liquid phase separation (LLPS) and β-sheet-rich hydrogel formation. PDCs with alternating L/D residues underwent LLPS in solution; all-L or all-D PDCs formed structured hydrogels. The chirality-controlled phase behavior is a design lever for PDC drug-product engineering: LLPS-prone conjugates dissolve readily for parenteral dosing, while hydrogel-forming variants enable sustained-release depots or injection-site retention. The work expands the design space for peptide-drug conjugate formulation, joining the broader May 2026 PDC research cycle alongside the Avacta AVA6103 FOCUS-01 trial start and the Bicycle Therapeutics ASCO Duravelo-2 readout.
A Molecular Therapy Oncology 2026 paper from a multi-institution collaboration reported that a peptide engineered against Fibulin-4 — a glycoprotein overexpressed in metastatic breast cancer extracellular matrix — successfully targeted and killed metastatic breast cancer cells in mice. The same peptide doubles as an imaging probe, supporting peptide-based detection alongside therapy. The Fibulin-4 target is significant because metastatic breast cancer remains the leading cause of breast cancer mortality and current targeted therapies (HER2, hormone-receptor) leave a substantial therapy gap for triple-negative metastatic disease. The work joins the broader peptide-drug-conjugate field in which six PDCs are in Phase 3 trials and roughly 96 are in development, even as only Lutathera holds active FDA approval after the 2024 Pepaxto withdrawal.
Oncopeptides announced on Monday, May 11, 2026 that it intends to submit a Type II variation application to the European Medicines Agency to extend the Pepaxti (melflufen) label to third-line multiple myeloma, with first regulatory feedback expected before the end of 2026 and a European Commission decision in the first half of 2027. Pepaxti, a peptide-drug conjugate given with dexamethasone, is authorized in the EU for adults who have had at least three prior lines of therapy and whose disease is refractory to a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody. The company said a third-line label would double Pepaxti's addressable patient population in Europe. The drug is not available in the U.S.: the FDA withdrew its approval, under the name Pepaxto, on February 23, 2024.
Avacta Therapeutics's AVA6000, a fibroblast activation protein (FAP)-activated peptide-drug conjugate releasing doxorubicin selectively in the tumor microenvironment, will be presented at ASCO 2026 (Chicago, May 29-June 2) covering Phase Ia/Ib data in FAP-positive solid tumors with activity against salivary gland cancers — a rare cancer subset with no approved targeted therapies. The pre|CISION platform attaches a peptide tetrazolyl moiety that is cleaved by FAP, an enzyme overexpressed in cancer-associated fibroblasts and selectively present in the tumor stroma, allowing systemic dosing without the cardiotoxicity that limits free doxorubicin. AVA6000 joins Bicycle's nuzefatide pevedotin and Lilly's CRN09682 in the broader peptide-drug conjugate Phase 2/3 cohort.